2023-05-24 10:25:09 ET
- Medical device maker ClearPoint Neuro ( NASDAQ: CLPT ) announced Wednesday a multi-year license agreement with UCB ( OTCPK:UCBJF ) ( OTCPK:UCBJY ) to develop drug delivery platforms for Belgian biopharma’s gene therapy portfolio.
- Per the terms, UCB ( OTCPK:UCBJF ) will use ClearPoint’s ( CLPT ) technology and services to develop and commercialize its gene therapy products. In return, the U.S.-based firm will receive success-based milestone payments. Other financial terms of the transaction were not disclosed.
- “We believe that ClearPoint Neuro are a strong strategic fit for UCB as they are a company dedicated to innovation in the neurology space with a unique portfolio of navigation and drug delivery tools,” Chief Scientific Officer of UCB ( OTCPK:UCBJF ) Dhaval Patel noted.
- On Wednesday, the Brussels-headquartered firm announced a collaboration with U.S. Cloud-based software solution provider Veeva Systems ( VEEV ) to bring tech- driven solutions for clinical studies.
For further details see:
ClearPoint Neuro in pact with UCB for gene therapy delivery